NPF-Led Research and Publications

NPF is committed to leading collaborative, transformational research that leads to better treatments and a cure for psoriatic disease. This is a collection of publications that NPF staff and partners have contributed to.

Medical Board and Scientific Advisory Committee Papers

2021

Armstrong A, Lebwohl M, Merola JF, Koons S, Fried R, Hawkes J, et al. Non-Medical Switching Impact on Patients and Providers – Psoriatic Disease Community Taking a Stand. Journal of psoriasis and psoriatic arthritis. 2021:24755303211024205 https://doi.org/10.1177/24755303211024205.

Yan D, Gudjonsson JE, Le S, Maverakis E, Plazyo O, Ritchlin C, et al. New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. Journal of Investigative Dermatology. 2021;141(9):2112-22.e3 https://dx.doi.org/10.1016/j.jid.2021.02.764.

Yan D, Blauvelt A, Dey AK, Golpanian RS, Hwang ST, Mehta NN, et al. New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies. Journal of Investigative Dermatology. 2021;141(10):2328-37 https://dx.doi.org/10.1016/j.jid.2021.02.743.

2019

Baumrin E, Van Voorhees A, Garg A, Feldman SR, Merola JF. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2019;81(1):102-10 https://pubmed.ncbi.nlm.nih.gov/30885757/.

2018

Ford AR, Siegel M, Bagel J, Cordoro KM, Garg A, Gottlieb A, et al. Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. JAMA dermatology. 2018;154(8):934-50 https://pubmed.ncbi.nlm.nih.gov/29926091/.

Prussick R, Wu JJ, Armstrong AW, Siegel MP, Van Voorhees AS. Psoriasis in solid organ transplant patients: best practice recommendations from The Medical Board of the National Psoriasis Foundation. The Journal of dermatological treatment. 2018;29(4):329-33 https://pubmed.ncbi.nlm.nih.gov/28884635/.

Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, et al. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2018;78(2):383-94 https://pubmed.ncbi.nlm.nih.gov/29332708/.

2017

Khosravi H, Siegel MP, Van Voorhees AS, Merola JF. Treatment of Inverse/Intertriginous Psoriasis: Updated Guidelines from the Medical Board of the National Psoriasis Foundation. Journal of drugs in dermatology: JDD. 2017;16(8):760-6 https://pubmed.ncbi.nlm.nih.gov/28809991/.

2016

Choi YM, Debbaneh M, Weinberg JM, Yamauchi PS, Van Voorhees AS, Armstrong AW, et al. From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology. 2016;75(4):798-805.e7 https://pubmed.ncbi.nlm.nih.gov/27461230/.

2015

Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA dermatology. 2015;151(4):432-8 https://pubmed.ncbi.nlm.nih.gov/25517130/.

Crowley JJ, Weinberg JM, Wu JJ, Robertson AD, Van Voorhees AS. Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA dermatology. 2015;151(1):87-94 https://pubmed.ncbi.nlm.nih.gov/25471223/.

2014

Hugh J, Van Voorhees AS, Nijhawan RI, Bagel J, Lebwohl M, Blauvelt A, et al. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. Journal of the American Academy of Dermatology. 2014;70(1):168-77 https://pubmed.ncbi.nlm.nih.gov/24184141/.

Motaparthi K, Stanisic V, Van Voorhees AS, Lebwohl MG, Hsu S. From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. Journal of the American Academy of Dermatology. 2014;70(1):178-86 https://pubmed.ncbi.nlm.nih.gov/24220724/.

2013

Wine-Lee L, Keller SC, Wilck MB, Gluckman SJ, Van Voorhees AS. From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis. Journal of the American Academy of Dermatology. 2013;69(6):1003-13 https://pubmed.ncbi.nlm.nih.gov/24075223/.

2012

Bae YS, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, et al. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2012;67(3):459-77 https://pubmed.ncbi.nlm.nih.gov/22018758/.

Robinson A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF, Jr., et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2012;67(2):279-88.

2011

anoGrozdev IS, Van Voorhees AS, Gottlieb AB, Hsu S, Lebwohl MG, Bebo BF, Jr., et al. Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2011;65(3):537-45 https://pubmed.ncbi.nlm.nih.gov/21496950/.

2010

Bremmer S, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, et al. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2010;63(6):1058-69 https://pubmed.ncbi.nlm.nih.gov/20692722/.

Menon K, Van Voorhees AS, Bebo BF, Jr., Gladman DD, Hsu S, Kalb RE, et al. Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2010;62(2):291-9 https://pubmed.ncbi.nlm.nih.gov/19646777/.

Rosenbach M, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF, Jr., et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2010;62(4):655-62 https://pubmed.ncbi.nlm.nih.gov/19665821/.

2009

Chan CS, Van Voorhees AS, Lebwohl MG, Korman NJ, Young M, Bebo BF, Jr., et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2009;60(6):962-71 https://pubmed.ncbi.nlm.nih.gov/19375191/.

Frankel AJ, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF, Jr., et al. Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2009;61(6):1044-55 https://pubmed.ncbi.nlm.nih.gov/19811848/.

Kalb RE, Bagel J, Korman NJ, Lebwohl MG, Young M, Horn EJ, et al. Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology. 2009;60(1):120-4 https://pubmed.ncbi.nlm.nih.gov/19103363/.

2008

Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. Journal of the American Academy of Dermatology. 2008;58(1):94-105 https://pubmed.ncbi.nlm.nih.gov/17980456/.

NPF Team Publications

2021

Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, et al. National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 2 - Advances in Psoriatic Disease Management, COVID-19 Vaccines, and COVID-19 Treatments. Journal of the American Academy of Dermatology. 2021 https://pubmed.ncbi.nlm.nih.gov/33422626/.

Gondo GC, Merola JF, Bell S, Blauvelt A. Decreased quality of life in people with psoriasis and psoriatic arthritis versus people with psoriasis alone: data from a national US survey. The British journal of dermatology. 2021. https://pubmed.ncbi.nlm.nih.gov/34289088/

Gondo GC, Koons S, Metcalf C, Bell SJ, Mehta NN. Viewing Psoriasis as a Systemic Disease for Better Health Outcomes. JID Innovations. 2021:100007 https://www.sciencedirect.com/science/article/pii/S2667026721000072.

Gondo GC, Bell SJ, Slayden J, Ullmann G, Blauvelt A. Concerns and perceptions of patients with psoriatic disease during the COVID-19 pandemic: results from a two-wave survey by the National Psoriasis Foundation. Journal of the European Academy of Dermatology and Venereology. 2021;35(6):e354-e5 https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.17173.

Gisondi P, Bellinato F, Targher G, Idolazzi L, Girolomoni G. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Annals of the rheumatic diseases. 2021. https://pubmed.ncbi.nlm.nih.gov/34144965/

Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis Prevalence in Adults in the United States. JAMA dermatology. 2021 https://doi.org/10.1001/jamadermatol.2021.2007.

Armstrong AW, Archuleta L, Gutierrez Y, Liao W, Bell SJ, Gondo G. Validation of Patient-Reported Psoriasis Diagnosis from a Global Online Research Network. Journal of Investigative Dermatology. 2021 https://doi.org/10.1016/j.jid.2021.03.021.

Gondo G, Heydon S, Bell S. Perspective of psoriatic disease patients on novel COVID-19 vaccines. Journal of Investigative Dermatology. 2021;141(5):S66 https://doi.org/10.1016/j.jid.2021.02.403.

Gondo G, Bell S, Merola J, Gottlieb A. Differences in musculoskeletal impact on health among patients with psoriasis based on disease type, disease severity and undiagnosed psoriatic arthritis (PsA). Journal of Investigative Dermatology. 2021;141(5):S67 https://doi.org/10.1016/j.jid.2021.02.406.

Gondo G, Hadeler E, Brownstone N, Maverakis E, Merola J, Armstrong A, et al. Demographic and clinical factors associated with patient-reported remission in psoriasis. Journal of Investigative Dermatology. 2021;141(5):S71 https://doi.org/10.1016/j.jid.2021.02.434.

Gondo G, Mosca M, Hong J, Maverakis E, Armstrong A, Merola J, et al. Demographic and clinical factors associated with patient-reported remission in psoriatic arthritis. Journal of Investigative Dermatology. 2021;141(5):S51 https://doi.org/10.1016/j.jid.2021.02.313.

2020

Enos CW, Galadima H, Saini AD, Bell S, Siegel M, Van Voorhees AS. Predictors of Biologic Use and Satisfaction Among Patients With Psoriasis: An Analysis and Geographic Visualization of the 2016 and 2017 National Psoriasis Foundation Annual Surveys. Journal of psoriasis and psoriatic arthritis. 2020;5(3):100-8 https://journals.sagepub.com/doi/abs/10.1177/2475530320925553.

Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, et al. National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. Journal of the American Academy of Dermatology. 2020;83(6):1704-16 https://www.ncbi.nlm.nih.gov/pubmed/32891785.

Gondo G, Boles J, Stone P, Howard L, Bell SJ. Prevalence of Utilization Management Policies Among the Psoriatic Disease Community: Results From the 2019 National Psoriasis Foundation Advocacy Survey. Journal of psoriasis and psoriatic arthritis. 2020;5(04):2475530320956602 https://journals.sagepub.com/doi/abs/10.1177/2475530320956602.

Gondo G, Domire J, Merola JF, Gottlieb A, Bell S. Understanding the impact of psoriatic disease on mental health: Results from the National Psoriasis Foundation Annual Survey. Journal of Investigative Dermatology. 2020;140(7):S61 https://doi.org/10.1016/j.jid.2020.03.467.

Merola JF, Gondo G, Bell S, Callis Duffin K, Gottlieb A. Understanding the prevalence of potentially undiagnosed psoriatic arthritis and the impact on patient quality of life: Results from the National Psoriasis Foundation's Annual Survey. 29th Annual Congress of the European Academy of Dermatology and Venerology; Vienna, Austria 2020.

Merola JF, Perez Chada LM, Siegel M, Bagel J, Evans C, Lockshin B, et al. The National Psoriasis Foundation psoriasis treatment targets in real-world patients: prevalence and association with patient-reported outcomes in the Corrona Psoriasis Registry. Journal of the European Academy of Dermatology and Venereology. 2020;34(9):2051-8 https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.16274.

Bell S, Merola JF, Webster DE, Pennington SR, Liao W, Ogdie A, et al. Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. Curr Rheumatol Rep. 2020;22(11):78 https://pubmed.ncbi.nlm.nih.gov/32959152/.

Bell S, Nahle Z, Adamopoulos IE. Psoriatic arthritis; overcoming the challenges by creating opportunities. Clin Immunol. 2020;218:108519 https://pubmed.ncbi.nlm.nih.gov/32621978/.

2019

Smith MP, Ly K, Thibodeaux Q, Weerasinghe T, Beck K, Shankle L, et al. Factors Influencing Sleep Difficulty and Sleep Quantity in the Citizen Pscientist Psoriatic Cohort. Dermatology and therapy. 2019;9(3):511-23 https://www.ncbi.nlm.nih.gov/pubmed/31177381.

Teeple A, Ellis LA, Huff L, Reynolds C, Ginsburg S, Howard L, et al. Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States. Curr Med Res Opin. 2019;35(4):611-7 https://pubmed.ncbi.nlm.nih.gov/30712393/.

Teeple A, Ginsburg S, Howard L, Huff L, Reynolds C, Walls D, et al. Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States. Curr Med Res Opin. 2019;35(4):603-9 https://pubmed.ncbi.nlm.nih.gov/30618353/.

2016

Albrecht J, Lebwohl M, Asgari MM, Bennett DD, Cook A, Evans CC, et al. The state and consequences of dermatology drug prices in the United States. Journal of the American Academy of Dermatology. 2016;75(3):603-5 https://www.ncbi.nlm.nih.gov/pubmed/27423978.

McCormick Howard L. National Psoriasis Foundation: a patient-centric approach to improve access to psoriatic disease treatment. Am J Manag Care. 2016;22(4 Suppl):s104-7 https://pubmed.ncbi.nlm.nih.gov/27270154/.

2014

Duffin KC, Yeung H, Takeshita J, Krueger GG, Robertson AD, Troxel AB, et al. Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. The British journal of dermatology. 2014;170(3):672-80 https://pubmed.ncbi.nlm.nih.gov/24266717/.

Takeshita J, Callis Duffin K, Shin DB, Krueger GG, Robertson AD, Troxel AB, et al. Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. Journal of the American Academy of Dermatology. 2014;71(4):633-41 https://www.ncbi.nlm.nih.gov/pubmed/24928705.

2013

Abuabara K, Wan J, Troxel AB, Shin DB, Van Voorhees AS, Bebo BF, Jr., et al. Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis. Journal of the American Academy of Dermatology. 2013;68(2):262-9 https://www.ncbi.nlm.nih.gov/pubmed/22910105.

Bhutani T, Wong JW, Bebo BF, Armstrong AW. Access to health care in patients with psoriasis and psoriatic arthritis: data from National Psoriasis Foundation survey panels. JAMA dermatology. 2013;149(6):717-21 https://pubmed.ncbi.nlm.nih.gov/23783152/.

Helmick CG, Sacks JJ, Gelfand JM, Bebo B, Jr., Lee-Han H, Baird T, et al. Psoriasis and psoriatic arthritis: a public health agenda. American journal of preventive medicine. 2013;44(4):424-6 https://www.ncbi.nlm.nih.gov/pubmed/23498110.

Yeung H, Wan J, Van Voorhees AS, Callis Duffin K, Krueger GG, Kalb RE, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. Journal of the American Academy of Dermatology. 2013;68(1):64-72 https://www.ncbi.nlm.nih.gov/pubmed/22846688.

2012

Armstrong AW, Schupp C, Bebo B. Psoriasis Comorbidities: Results from the National Psoriasis Foundation Surveys 2003 to 2011. Dermatology. 2012;225(2):121-6 https://pubmed.ncbi.nlm.nih.gov/23108113/.

Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One. 2012;7(12):e52935 https://www.ncbi.nlm.nih.gov/pubmed/23285231.

2005

Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, et al. Epidemiology of psoriatic arthritis in the population of the United States. Journal of the American Academy of Dermatology. 2005;53(4):573 https://pubmed.ncbi.nlm.nih.gov/16198775/.

Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, et al. The prevalence of psoriasis in African Americans: results from a population-based study. Journal of the American Academy of Dermatology. 2005;52(1):23-6. https://pubmed.ncbi.nlm.nih.gov/15627076/.

Nijsten T, Margolis DJ, Feldman SR, Rolstad T, Stern RS. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. Journal of the American Academy of Dermatology. 2005;52(3 Pt 1):434-44 https://www.ncbi.nlm.nih.gov/pubmed/15761421.

2004

Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. Journal of the American Academy of Dermatology. 2004;51(5):704-8 https://pubmed.ncbi.nlm.nih.gov/15523347/.

Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136-9 https://pubmed.ncbi.nlm.nih.gov/15083780/.

2001

Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Archives of dermatology. 2001;137(3):280-4 https://pubmed.ncbi.nlm.nih.gov/11255325/.

AAD-NPF Guidelines

All Years

Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of Dermatology. 2019;80(4):1073-113 https://doi.org/10.1016/j.jaad.2018.11.058.

Elmets CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. Journal of the American Academy of Dermatology. 2019;81(3):775-804 https://www.ncbi.nlm.nih.gov/pubmed/31351884.

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology. 2019;80(4):1029-72 https://www.ncbi.nlm.nih.gov/pubmed/30772098.

Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. Journal of the American Academy of Dermatology. 2020 https://www.ncbi.nlm.nih.gov/pubmed/32738429.

Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. Journal of the American Academy of Dermatology. 2020;82(6):1445-86 https://www.ncbi.nlm.nih.gov/pubmed/32119894.

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity Navigator

Copyright © 1996-2021 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.